Advertisement

Topics

PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes

16:15 EDT 4 Aug 2017 | SCRIP

Amgen's report of higher sales and news of priority review for an outcomes benefit claim for Repatha bode well, but...

      

Related Stories

 

Original Article: PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes

NEXT ARTICLE

More From BioPortfolio on "PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...